Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
On Monday, Revelation Biosciences Inc (NASDAQ:REVB) announced safety and biomarker data for its Phase 1 study (RVL-HV02).
週一，Revelation Biosciences Inc（納斯達克：REVB）宣佈其一期研究（RVL-HV02）的安全性和生物標誌物數據。
The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified.
評估升級劑量Gemini的安全性和耐受性的主要終點已得到滿足，並確定了健康志願者的最大耐受劑量。
Additionally, statistically significant dose-dependent upregulation of key biomarkers demonstrating the immunostimulatory preconditioning effect of Gemini was observed.
此外，觀察到關鍵生物標誌物的劑量依賴性上調，表明Gemini具有免疫前調效應，達到統計顯著性。
The study enrolled 40 healthy individuals 18 to 55 years of age.
該研究招募了40名年齡在18至55歲的健康個體。
Administration of Gemini induced significant, dose-dependent changes in key circulatory biomarkers of activity that reflect the expected pharmacology of Gemini-specific toll-like receptor 4 (TLR4) stimulation.
Gemini的靜脈注射引起了循環生物標誌物活動的顯著、劑量依賴性變化，反映了特異性toll樣受體4（TLR4）激活的藥理學預期。
Intravenous Gemini induced significant increases in interleukin-1RA (IL-1RA) (p<0.001 at mid and high dose), neutrophil gelatinase lipocalin (NGAL) (p<0.01 at mid and high dose), c-reactive protein (CRP) (p<0.001 at mid and high dose), and IL-6 (p<0.01 at high dose).
靜脈注射Gemini顯著增加了白細胞介素1RA（IL-1RA）（中、高劑量p
Significant, dose-dependent mobilization of innate immune cell populations was observed, specifically neutrophils (p<0.001 at mid-dose and high dose) and monocytes (p<0.001 at mid and high dose).
觀察到顯著、劑量依賴性的先天免疫細胞群體動員，特別是中性粒細胞（中劑量和高劑量p
Gemini administration did not induce significant increases in serum TNF-α (p=0.51 at the highest dose) and IL-1β (p=0.89 at the highest dose).
Gemini注射未引起血清TNF-α（最高劑量p = 0.51）和IL-1β（最高劑量p = 0.89）的顯著增加。
Gemini administration was generally well-tolerated.
Gemini注射通常耐受。
"With this new data, we are excited and committed to moving rapidly into a Phase 1b study in patients in late 2024," said James Rolke, Chief Executive Officer of Revelation.
“有了這個新數據，我們很興奮並致力於2024年底快速進入患者的1b期研究，” Revelation首席執行官James Rolke表示。
Gemini is initially being developed as a single-dose preconditioning therapy for two target indications:
Gemini最初作爲兩個目標適應症的單劑量預處理療法開發：
- As a pretreatment to prevent or reduce the severity of acute kidney injury due to cardiac surgery (GEMINI-AKI program).
- As a pretreatment to reduce the incidence, duration, and severity of post-surgical infection (GEMINI-PSI program).
- 作爲預處理以防止或減輕因心臟手術而導致的急性腎損傷（GEMINI-AKI計劃）。
- 作爲預處理以減少手術後感染的發生率、持續時間和嚴重程度（GEMINI-PSI計劃）。
Price Action: REVB shares are up 31.30% at $2.77 at the last check on Monday.
價格行動：REVB股票在週一最後交易時上漲31.30％，至2.77美元。